Incidence and Management of Transtuzumab Emtansine- and Transtuzumab Deruxetecan-related Pneumonitis in Breast Cancer Patients within Leicester

Purpose: Antibody drug conjugates (ADC) are an emerging class of therapeutic agent. Transtuzumab emtansine (TDM1) was the first ADC approved in HER2-positive metastatic breast cancer in the UK [1] and subsequently in the early disease setting in 2020 [2]. As a result of DESTINY-Breast0 [3] and DESTINY-Breast 03 [4], transtuzumab deruxtecan (TDXd) was approved recently in the second-line metastatic setting. Interstitial lung disease (ILD) is a well-known treatment limiting toxicity of ADC; occurring in 2 –3% and 10–15% of patients receiving TDM1 and TDXd, respectively.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research